Fourrts (india) Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Fourrts (india) Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 17 Products, $31.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fourrts (india) Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 17 Products, $31.5M Trade | TransData Nexus

Fourrts (india) Laboratories Private Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $31.5M Total Trade · DGFT Verified

Fourrts (india) Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $31.5M across 17 products in 11 therapeutic categories. Based on 763 verified export shipments from Indian Customs (DGFT) records, Fourrts (india) Laboratories Private Limited is the #1 Indian exporter in 1 product including Cetirizine. Top exports include Metformin ($5.1M), Ibuprofen ($4.4M), Paracetamol ($4.2M).

Fourrts (india) Laboratories Private Limited — Export Portfolio & Destination Treemap

Fourrts (india) Laboratories Private Limited pharmaceutical export portfolio — 17 products across 11 therapeutic categories. Source: Indian Customs (DGFT).

Who is Fourrts (india) Laboratories Private Limited? — Company Overview & Market Position

Fourrts (India) Laboratories Private Limited, established on March 31, 1979, is a privately held pharmaceutical company headquartered in Chennai, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U85185TN1979PTC007782. As of the latest available data, Fourrts has an authorized share capital of ₹100 crore and a paid-up capital of ₹62.94 crore. The company is classified as a non-government company limited by shares.

Over the years, Fourrts has grown to become one of India's fastest-growing pharmaceutical companies, with a dedicated team of over 2,500 professionals. The company's products are available in more than 50 countries worldwide, reflecting its significant global presence.

What Does Fourrts (india) Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Metformin$5.1M 2Ibuprofen$4.4M

Product Portfolio — Top 17 by Export Value

Fourrts (india) Laboratories Private Limited exports 17 pharmaceutical products across 11 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Metformin	Diabetes & Endocrine	$5.1M	102	1.1%	12
2	Ibuprofen	Analgesics & Antipyretics	$4.4M	88	0.8%	10
3	Paracetamol	Analgesics & Antipyretics	$4.2M	83	1.2%	8
4	Cetirizine	Antihistamines & Allergy	$4.0M	80	2.2%	1
5	Naproxen	Analgesics & Antipyretics	$3.6M	127	2.7%	10
6	Atenolol	Cardiovascular	$1.4M	51	3.5%	7
7	Furosemide	Diuretics	$1.2M	56	1.8%	13
8	Salbutamol	Respiratory	$1.2M	24	0.8%	5
9	Trimethoprim	Advanced Antibiotics	$1.1M	22	4.0%	5
10	Fluconazole	Antifungals	$1.1M	21	1.1%	10
11	Sulfamethoxazole	Advanced Antibiotics	$1.0M	20	5.1%	3
12	Ambroxol	Respiratory & OTC	$958.0K	22	6.5%	4
13	Pyrimethamine	Antimalarial & Antiparasitic	$750.0K	15	1.6%	4
14	Cefixime	Advanced Antibiotics	$450.0K	9	0.3%	7
15	Griseofulvin	Advanced Antifungals	$450.0K	9	1.2%	9
16	Propranolol	Cardiovascular	$435.6K	16	0.4%	10
17	Mebendazole	Antimalarial & Antiparasitic	$256.0K	18	1.9%	8

Fourrts (india) Laboratories Private Limited exports 17 pharmaceutical products across 11 therapeutic categories with a total export value of $31.5M. The company is the #1 Indian exporter in 1 product: Cetirizine. The top category is Analgesics & Antipyretics (38.5% of portfolio), followed by Diabetes & Endocrine (16.2%), indicating a concentrated portfolio with the top 5 products accounting for 67.4% of total export value.

Fourrts (india) Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Fourrts operates two state-of-the-art manufacturing facilities:

Plant I: A WHO-GMP certified facility accredited by Bureau Veritas for ISO 9001:2015. This plant caters to emerging markets, with products present in over 40 countries. Its capabilities include the production of coated and uncoated tablets, capsules, liquid orals, creams, ointments, and medicated toothpaste.

Plant II: A world-class facility approved by the US FDA, UK MHRA, EU GMP, Saudi FDA, Health Canada, and TGA Australia. With a production capacity of 4 billion tablets and 350 million capsules annually, Plant II specializes in contract manufacturing (CMO) and formulation development (CDMO) services.

3Key Leadership

The leadership team at Fourrts includes:

Sekharipuram Viswanathan Veeramani: Managing Director since the company's inception in 1979.

Veerramani Radha: Director since October 31, 1991.

Mohan Lakshminarayan Iyer: Additional Director since December 15, 2021.

Nitia Mohan: Additional Director since December 15, 2021.

Gayatri Veeramani Jayaraman: Additional Director since December 15, 2021.

Sundar Jayaraman: Additional Director since December 15, 2021.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Fourrts (india) Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Fourrts has established a strong presence in several regulated markets:

United States: The company has a manufacturing facility approved by the US FDA, indicating compliance with stringent US regulatory standards.

European Union: Fourrts' Plant II holds EU GMP certification, ensuring adherence to European manufacturing standards.

United Kingdom: The company's manufacturing facility is approved by the UK MHRA, reflecting compliance with UK regulatory requirements.

Australia: Fourrts' Plant II is approved by the TGA Australia, demonstrating adherence to Australian manufacturing standards.

These approvals facilitate Fourrts' market access and distribution in these regions.

2Emerging Markets

Fourrts (india) Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Fourrts' manufacturing facility is registered with the US FDA, indicating compliance with US regulatory standards.

2WHO & EU GMP

The company holds WHO-GMP certification for Plant I and EU GMP certification for Plant II, ensuring adherence to international manufacturing standards.

3CDSCO & Indian Regulatory

Fourrts operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India, ensuring compliance with national pharmaceutical regulations.

4Recent Regulatory Actions

As of the latest available data, there are no reported FDA Form 483 observations, warning letters, or import alerts associated with Fourrts.

Fourrts (india) Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the analgesics and antipyretics category, Fourrts' top products include Metformin, Ibuprofen, Paracetamol, Cetirizine, and Naproxen. The company holds a 2.2% market share in Cetirizine, positioning it as a market leader in this segment.

2Key Differentiators

Fourrts' key differentiators include its strong commitment to ethical practices, innovative product development, and adherence to high-quality manufacturing standards. The company's extensive experience and global presence further distinguish it in the pharmaceutical industry.

3Strategic Position

Fourrts' current strategic direction focuses on expanding its presence in both regulated and emerging markets, with a strong emphasis on contract manufacturing and formulation development services. The company's future outlook includes continued growth through innovation and adherence to international quality standards.

TransData Nexus Research · DGFT export records, industry analysis

Buyer Due Diligence Brief — Evaluating Fourrts (india) Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Fourrts has a robust track record in pharmaceutical manufacturing, with a significant export volume and consistency in product quality. The company's adherence to international regulatory standards and certifications indicates reliability and trustworthiness as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Fourrts as a supplier:

FDA Approval: Confirm the facility's registration with the US FDA.

WHO-GMP Certification: Verify the WHO-GMP certification for Plant I.

EU GMP Certification: Ensure the EU GMP certification for Plant II.

ISO 9001:2015 Certification: Check the ISO 9001:2015 accreditation by Bureau Veritas.

Frequently Asked Questions — Fourrts (india) Laboratories Private Limited

How many pharmaceutical products does Fourrts (india) Laboratories Private Limited export from India?

Fourrts (india) Laboratories Private Limited exports 17 pharmaceutical products across 11 therapeutic categories. The top exports are Metformin ($5.1M), Ibuprofen ($4.4M), Paracetamol ($4.2M), Cetirizine ($4.0M), Naproxen ($3.6M). Total export value is $31.5M.

What is Fourrts (india) Laboratories Private Limited's total pharmaceutical export value?

Fourrts (india) Laboratories Private Limited's total pharmaceutical export value is $31.5M, based on 763 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Fourrts (india) Laboratories Private Limited the #1 Indian exporter?

Fourrts (india) Laboratories Private Limited is the #1 Indian exporter in 1 products: Cetirizine (2.2% market share).

What therapeutic categories does Fourrts (india) Laboratories Private Limited cover?

Fourrts (india) Laboratories Private Limited exports across 11 therapeutic categories. The largest are Analgesics & Antipyretics (38.5%, 3 products), Diabetes & Endocrine (16.2%, 1 products), Antihistamines & Allergy (12.7%, 1 products).

Get Full Fourrts (india) Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.